Amryt Pharma PLC Notice of Results (7571O)
August 23 2017 - 2:30AM
UK Regulatory
TIDMAMYT
RNS Number : 7571O
Amryt Pharma PLC
23 August 2017
23 August 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Notice of Interim Results
Amryt Pharma, the biopharmaceutical company focused on
innovative therapies for patients with rare and orphan diseases,
will announce interim results, covering the six months to 30 June
2017, on Monday, 4 September 2017.
For further information on an analyst briefing to be held that
day, please contact KTZ Communications.
Enquiries:
Amryt Pharma plc C/o KTZ Communications
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Bidhi Bhoma, Edward Mansfield
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the EU and other territories
including the Middle East, North Africa, Turkey and Israel. Lojuxta
is used to treat a rare life-threatening disease called Homozygous
Familial Hypercholesterolemia, which impairs the body's ability to
remove LDL cholesterol ("bad" cholesterol) from the blood. This
typically results in extremely high blood LDL cholesterol levels,
leading to aggressive and premature narrowing and blocking of
arterial blood vessels. If left untreated, heart attack or sudden
death may occur in childhood or early adulthood.
Amryt's lead drug candidate, AP101 (Episalvan), is a potential
treatment for Epidermolysis Bullosa ("EB"), a rare and distressing
genetic skin disorder affecting young children for which there is
currently no treatment. It is currently in Phase 3 clinical trials.
The global market opportunity for EB is estimated to be in excess
of EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSEWSWDFWSEEA
(END) Dow Jones Newswires
August 23, 2017 03:30 ET (07:30 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024